Clinical TrialsSearch results
Number of results: 937
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Recruiting
- Research on the safety of hyperthermic chemotherapy administered at the time of resection of disseminated lesions for pleural dissemination of malignant tumors occurring in children and AYA generations
- pleural dissemination of malignant tumor
- Kitagawa Norihiko
- 2024-03-27
Recruiting
- H. pylori rescue eradication therapy with rifabutin, sitafloxacin, and vonoprazan
- Helicobacter pylori infection
- Sue Soichiro
- 2024-03-27
Recruiting
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer
- Breast Cancer
- Inoguchi Akihiro
- 2024-03-20
Recruiting
- Exploratory study using [11C]K-2 to identify brain regions that contribute to acquiring mental resilience based on AMPA receptor density
- Adverse Childhood Experiences
- Asami Takeshi
- 2024-03-18
Other
- Single-arm, Open-label, Phase 3, Multi-center Study to Evaluate the Safety and Efficacy of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Crohns Disease in Japan
- Crohn Disease
- Katsuyoshi Matsuoka
- 2024-03-15
Other
- Bioequivalence study of JTE-052
- atopic dermatitis
- Mitsui Hironori
- 2024-03-15
Other
- An open-label, uncontrolled, single-arm study of NT 201 in patients with cervical dystonia
- Cervical Dystonia
- Sasaki Yuzuru
- 2024-03-12
Recruiting
- A Study of Postpartum Depression, Nutrition, and Neonatal Physical Development.
- Postpartum depression
- Yamamoto Kenji
- 2024-03-12
Recruiting
- LOME-PECT trial
- Patients admitted to ICU (critically ill) who need to be controlled with EN preparations
- Nakamura Kensuke
- 2024-03-08
Recruiting
- A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC).
- Non-small Cell Lung Cancer
- Hibi Kazushige
- 2024-03-06